Why invest in Medical Cannabis for veterinary use?
The first cannabis-based medicine – Sativex – obtained regulatory registration and marketing authorization from the European agency EMA in 2018, followed by Epidiolex, authorized by the FDA in 2019. Today, there are numerous new medicines in human clinical studies authorized by the FDA (clinicaltrials.gov). More than 23 countries authorize the marketing of medicines for diseases such as epilepsy, multiple sclerosis, Parkinson's disease, glaucoma, and several other medical conditions that have a high degree of response to treatment with cannabidiol, as well as other components of the plant, without the aggressive side effects of commonly used treatments.
Animal health
No drugs are approved for veterinary use by the FDA, but they are already widely marketed as supplements (without technical rigor and validation) or consumer products. Confirmation of the therapeutic benefits of Cannabidiol for various animal health conditions is described in hundreds of articles published in peer-reviewed medical journals, among which we highlight some references (links).
Medical Cannabis for veterinary treatment in Brazil
In Brazil, there are approximately 15 cannabis-based medicines for humans approved by ANVISA (National Health Surveillance Agency). As for animals, the Brazilian reality is still quite different. Despite the numerous proven benefits for pets, from pain relief to seizures to the treatment of distemper and cancer, there are still no medicines in this class approved for prescription by veterinarians. Even so, owners from all over the country fight for and obtain exceptional authorizations, since cannabidiol is often much more effective than many other medicines and also has fewer side effects.
Advances for Pet Health and the Brazilian Economy
Vettiva's research advances are at the forefront of supporting innovation and the development of products and therapies for the treatment of thousands of animals in Brazil. Brazil is the country with the second largest population of domestic animals in the world, and the pet segment is driving the main growth in the national market (CAGR 7.1%, 2017-2024*), with a large market for innovative products.
We intend to be a national reference and distribute our medicines to several countries.